Abstracts tagged "Abatacept"

Abstract Number: 1928 • 2019 ACR/ARP Annual Meeting
Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Antonio Julià¹, Maria Lopez Lasanta ², Antonio Gómez ³, Irene Bonafonte ⁴, Raimon Sanmartí ⁵, Carlos Marras ⁶, José Manuel Pina ⁷, Susana Romero-Yuste ⁸, Raul Veiga ⁹, Pilar Navarro ⁹, Carmen Moragues Pastor ¹⁰, Silvia Martínez ¹¹, Francisco J. De Toro ¹², Amalia Sanchez ¹³, Dacia Cerdà ¹⁴, Alejandro Prada ¹⁵, Alba Erra ¹⁶, Jordi Monfort ¹⁷, A. Urruticoechea-Arana ¹⁸, Núria Palau ¹⁹, Raquel Lastra ²⁰, Raúl Tortosa ³, Andrea Pluma ²¹ and Sara Marsal ²², ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ⁴Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁵Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Hospital Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁷Hospital de Barbastro, Huesca, Barbastro, Huesca, Spain, ⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ⁹Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, ¹⁰Platò Hospital, Barcelona, Spain, Barcelona, Spain, ¹¹Hospital Universitari Mútua Terrassa, Terrassa, Spain, ¹²University Hospital A Coruña, A Coruña, Spain, ¹³Hospital Universitario Lucus Augusti, Lugo, Lugo, Spain, ¹⁴Hospital Moisès Broggi, Sant Joan Despí, Sant Joan Despí, Spain, ¹⁵Hospital Universitario Torrejón de Ardoz, Torrejón de Ardoz, Spain, ¹⁶Hospital Sant Rafael, Barcelona, Barcelona, Spain, ¹⁷Hospital del Mar, Barcelona, Spain, ¹⁸HU Can Misses, Ibiza, Spain, ¹⁹Hospital Vall Hebrón Barcelona, Barcelona, Spain, ²⁰Hospital Vall Hebron, Barcelona, Barcelona, Spain, ²¹Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²²Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Abatacept (CTLA4-Ig) is an approved biological therapy for the treatment of rheumatoid arthritis (RA). Similar to other biological agents, most patients (50-60%) respond significantly…
Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Kuan-Hsiang Gary Huang ⁷, Sean Connolly ⁷, Yedid Elbez ⁸, Karissa Lozenski ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Princeton, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
Abstract Number: 2707 • 2019 ACR/ARP Annual Meeting
Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Jordi Antón ⁴, Diego Viola ⁵, Bernard Lauwerys ⁶, Rubèn J Cuttica ⁷, Pierre Quartier ⁸, Elisabeth Gervais ⁹, Alexandre Belot ¹⁰, Kirsten Minden ¹¹, Thomas Lutz ¹², Rolando Cimaz ¹³, Mahmood M. T. M. Ally ¹⁴, Riana van Zyl ¹⁵, Inmaculada Calvo Penadés ¹⁶, Joe Zhuo ¹⁷, Robert Wong ¹⁸, Marleen Nys ¹⁹, Yedid Elbez ²⁰, Alberto Martini ²¹, Daniel J. Lovell ²² and Nicolino Ruperto ²³, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Hospital Sant Joan de Déu, Barcelona, Spain, ⁵CAICI Institute, Rosario City, Santa Fe State, Argentina, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁸Necker Hospital, Paris, France, ⁹CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁰Centre Hospitalier Universitaire de Lyon, Lyon, France, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²Heidelberg University Hospital, Heidelberg, Germany, ¹³Meyer Children's Hospital in Florence, Florence, Italy, ¹⁴University of Pretoria, Pretoria, South Africa, ¹⁵University of the Free State, Bloemfontein, South Africa, ¹⁶Hospital Univ. La Fe, Valencia, Spain, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Princeton, ¹⁹Bristol-Myers Squibb, Braine L’Alleud, Belgium, ²⁰Excelya, Boulogne-Billancourt, France, ²¹IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ²²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ²³Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Efficacy of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label, Phase III international study (NCT01844518).1 Pediatric patient-reported outcomes…
Abstract Number: 249 • 2019 ACR/ARP Annual Meeting
Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Damemarie Paul ¹, Xue Han², Irina Yermilov ³, Sarah Gibbs ³ and Michael Broder ³, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²Bristol-Myers Squibb Company, Princeton, NJ, ³Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Abatacept is recommended as first-line biologic therapy in adult patients with moderate to severe RA. We aimed to assess real-world 1-year treatment persistence in…
Abstract Number: 2708 • 2019 ACR/ARP Annual Meeting
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Alberto Berman ⁴, Inmaculada Calvo Penadés ⁵, Jordi Antón ⁶, Francisco Ávila-Zapata ⁷, Rubèn J Cuttica ⁸, Gerd Horneff ⁹, Robert Wong ¹⁰, Mehmooda Shaikh ¹¹, Johanna Mora ¹¹, Marleen Nys ¹², Daniel J. Lovell ¹³, Alberto Martini ¹⁴ and Nicolino Ruperto ¹⁵, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital Sant Joan de Déu, Barcelona, Spain, ⁷Star Medica Hospital, Merida, Yucatán, Mexico, ⁸Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Bristol-Myers Squibb, Princeton, NJ, ¹²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹⁴IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…
Abstract Number: 546 • 2019 ACR/ARP Annual Meeting
Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX
René Toes¹, Thomas Lehman ², Joshua Bryson ³, Amy Min Kim ², Sandhya Balachandar ², Sumanta Mukherjee ², Michael Maldonado ², Sean Connolly ² and Thomas Huizinga ¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Princeton
Background/Purpose: An emerging concept of “immunologic remission” in RA raises questions about the relevance of the RA autoantibody profile in patients (pts) who are otherwise…
Abstract Number: 2770 • 2019 ACR/ARP Annual Meeting
Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis Patients in Remission
Joanna Kedra¹, Philippe Dieudé ², Hubert Marotte ³, Alexandre Lafourcade ⁴, Emilie Ducourau ⁵, Thierry Schaeverbeke ⁶, Aleth Perdriger ⁷, Martin SOUBRIER ⁸, Jacques Morel ⁹, Arnaud Constantin ¹⁰, Emmanuelle Dernis ¹¹, Valérie Royant ¹², Jean-Hugues Salmon ¹³, Thao Pham ¹⁴, Jacques-Eric Gottenberg ¹⁵, Edouard Pertuiset ¹⁶, Maxime Dougados ¹⁷, Valérie Devauchelle Pensec ¹⁸, Philippe Gaudin ¹⁹, gregoire Cormier ²⁰, Philippe Goupille ²¹, Xavier Mariette ²², Francis Berenbaum ²³, Didier Alcaix ²⁴, Sid-Ahmed Rouidi ²⁵, Jean-Marie Berthelot ²⁶, Agnès Monnier ²⁷, Christine Piroth ²⁸, Frédéric Lioté ²⁹, Vincent Goeb ³⁰, Cécile Gaujoux-Viala ³¹, Isabelle Chary-Valckenaere ³², David Hajage ⁴, Florence Tubach ³³ and Bruno Fautrel ³⁴, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, ²Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, ³University Hospital, St Etienne, France, ⁴Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ⁵Rheumatology Department, CHR Orléans, Orléans, France, ⁶FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁷Rheumatology department, Rennes University Hospital, France, Rennes, France, ⁸CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, ⁹CHU MONTPELLIER, MONTPELLIER, France, ¹⁰Hôpital Pierre-Paul Riquet, Toulouse, France, ¹¹Rheumatology Department, Le Mans Central Hospital, Le Mans, France, ¹²Rheumatology Department, Chartres Hospital, Chartres, France, ¹³Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁴Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ¹⁵Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁶Rheumatology Department, Pontoise Hospital, Pontoise, France, Pontoise, France, ¹⁷Cochin Hospital, Paris, France, ¹⁸University Hospital of Brest, Brest, France, ¹⁹Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ²⁰CHD Vendée, La Roche sur Yon, France, ²¹Tours University-Hospital, Tours, France, Tours, France, ²²Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ²³Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France, ²⁴Rheumatology Department, Le Havre Hospital, Le Havre, ²⁵Rheumatology Department, Dreux, France, ²⁶University Hospital, Nantes, France, ²⁷Internal Medicine Department, CH Côte Basque, Bayonne, France, ²⁸Rheumatology Department, Dijon Hospital, Dijon, France, ²⁹Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France, ³⁰Rheumatology Department, Amiens University Hospital, Amiens, France, ³¹Nîmes University Hospital, Nîmes, France, ³²Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ³³Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³⁴Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARD) tapering is proposed by clinical practice guidelines in rheumatoid arthritis (RA) patients in sustained remission. However, no randomized…
Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Xue Han¹, Joshua Bryson ¹, David C Crosby ¹, Michael Evans ² and Gabriela Schmajuk ³, ¹Bristol-Myers Squibb, Princeton, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
Abstract Number: 2915 • 2019 ACR/ARP Annual Meeting
Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
Bhaven Mehta ¹, Jennifer Franks ¹, Yiwei Yuan ², Yue Wang ¹, Veronica Berrocal ³, Tammara Wood ¹, Cathie Spino ⁴, David Fox ⁵, Dinesh Khanna ⁶ and Michael Whitfield⁷, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Geisel School of Medicine at Dartmouth, Hanover, ³Department of Biostatistics, School of Publich Health, University of Michigan, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Ann Arbor, ⁶Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁷Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hannover, NH
Background/Purpose: We analyzed a phase 2 study designed to assess the efficacy of abatacept in patients with diffuse Systemic Sclerosis (SSc). In this work, we…
Abstract Number: 1394 • 2019 ACR/ARP Annual Meeting
Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study
Leslie Harrold ¹, Joshua Bryson², Thomas Lehman ³, Joe Zhuo ³, Sheng Gao ³, Xue Han ⁴, Amy Schrader ⁵, Sabrina Rebello ⁶ and Joel Kremer ⁷, ¹University of Massachusetts and Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb, Princeton, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb Company, Princeton, NJ, ⁵Corrona, LLC, Waltham, ⁶Corrona, LLC, Waltham, MA, ⁷Albany Medical College, Albany, NY
Background/Purpose: In the AMPLE trial, patients (pts) with RA with higher baseline anti-CCP2 antibody concentrations showed a better response to treatment with abatacept (ABA) than…
Abstract Number: 115 • 2018 ACR/ARHP Annual Meeting
CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients
Maurizio Cutolo¹, Paola Montagna², Stefano Soldano¹, Amelia Chiara Trombetta³, Barbara Ruaro⁴, Paola Contini⁵, Sabrina Paolino⁶, Carmen Pizzorni⁴, Elisa Alessandri⁴, Massimo Patanè¹, Alberto Sulli⁴, Stefano Scabini⁷, Emanuela Stratta⁷ and Renata Brizzolara¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital, Genova, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genova, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁵Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino, Genova, Italy, Genova, Italy, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, ⁷Oncologic Surgery, Department of Surgery, IRCCS Polyclinic San Martino, Genova, Italy, Genoa, Italy
Background/Purpose: CTLA4-Ig interacts with the cell surface costimulatory molecule CD86 and can downregulate the target cell activation [1]. Circulating fibrocytes (CFs) express markers of both…
Abstract Number: 563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Abatacept in Combination with MTX in Early, MTX-Naïve, Anti-Citrullinated Protein Antibody–Positive Patients with RA: Primary and 1-Year Results from a Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka², Vivian P. Bykerk³, Tom W.J. Huizinga⁴, Gustavo Citera⁵, Marleen Nys⁶, Sean E. Connolly⁷, Alyssa Johnsen⁷ and Roy Fleischmann⁸, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Hospital for Special Surgery, New York, NY, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients (pts) with early (disease duration ≤24 months [mths]), MTX-naïve RA and poor prognostic factors including anti-citrullinated protein antibody (ACPA) positivity (+), abatacept…
Abstract Number: 900 • 2018 ACR/ARHP Annual Meeting
Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis— Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study
Dinesh Khanna¹, Cathie Spino², Erica Bush³, Sindhu Johnson⁴, Lorinda Chung⁵, Jerry Molitor⁶, Virginia D. Steen⁷, Robert Lafyatis⁸, Robert W. Simms⁹, Christopher P. Denton¹⁰, Suzanne Kafaja¹¹, Tracy M. Frech¹², Vivien Hsu¹³, Robyn T. Domsic¹⁴, Janet E. Pope¹⁵, Jessica K. Gordon¹⁶, Maureen D. Mayes¹⁷, Elena Schiopu³, Amber Young¹, Nora Sandorfi¹⁸, Jane Park¹⁹, Faye N. Hant²⁰, Elana J. Bernstein²¹, Soumya Chatterjee²², Flavia V. Castelino²³, Ali Ajam²⁴, Yannick Allanore²⁵, Marco Matucci-Cerinic²⁶, Oliver Distler²⁷, Ora Singer²⁸, Haoyan Zhong², David Fox²⁹ and Daniel E. Furst³⁰, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Biostatistics, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁷Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ⁸Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ¹¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹²Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ¹⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁶Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁷Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁸Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, ¹⁹Seattle Rheumatology Associates, Seattle, WA, ²⁰Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ²¹Rheumatology, Columbia University, New York, NY, ²²Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²³Rheumatology, Harvard Medical School, Boston, MA, ²⁴Division of Rheumatology-Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ²⁵Service de Rhumatologie A, Hôpital Cochin, Paris, France, ²⁶Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²⁸Medicine, University of Michigan, Ann Arbor, MI, ²⁹Internal Medicine, University of Michigan, Ann Arbor, MI, ³⁰UCLA, Los Angeles, CA
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein including extracellular domain of human CTLA4 and hinge‑ CH2‑CH3 of the Fc domain of human IgG. This…
Abstract Number: 971 • 2018 ACR/ARHP Annual Meeting
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis
Mary A. Dooley¹, Gerald B. Appel², Richard Furie³, David Wofsy⁴, Tsutomu Takeuchi⁵, Ana Malvar⁶, Andrea Doria⁷, Juanita Romero-Díaz⁸, Tak Mao Chan⁹, Ayanbola Elegbe¹⁰, David Jayne¹¹ and Michael A. Maldonado¹⁰, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Columbia University Medical Center, New York, NY, ³Northwell Health, New York, NY, ⁴University of California San Francisco, San Francisco, CA, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Nephrology Division, Hospital Fernández, Buenos Aires, Argentina, ⁷Division of Rheumatology, University of Padova, Padova, Italy, ⁸Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Bristol-Myers Squibb, Princeton, NJ, ¹¹University of Cambridge, Cambridge, United Kingdom
Background/Purpose: The tenets of novel treatment (tx) strategies for active class III/IV lupus nephritis (LN) aim to improve renal response rates, decrease extra-renal SLE disease…
Abstract Number: 1105 • 2018 ACR/ARHP Annual Meeting
Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis
Gonçalo Boleto¹, Christophe Guignabert², Sonia Pezet³, Anne Cauvet³, Jérémy Sadoine⁴, Ly Tu², Carole Nicco³, Camille Gobeaux⁵, Frederic Batteux³, Yannick Allanore³ and Jérôme Avouac¹, ¹Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital Cochin, Paris, France, Paris, France, ²INSERM UMR_S 999, Le Plessis-Robinson, France, Le Plessis-Robinson, France, ³Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France, Paris, France, ⁴EA 2496 Pathologie, Imagerie et Biothérapies Orofaciales, UFR Odontologie, Université Paris Descartes and PIDV, PRES Sorbonne Paris Cité, Montrouge, France, Montrouge, France, ⁵Clinical Chemistry Laboratory, Cochin and Hôtel-Dieu Hospitals, Paris, France, Paris, France
Background/Purpose: A previous report showed that abatacept (IgG-CTLA-4) prevented and induced regression of inflammation-driven dermal fibrosis in two different mouse models of systemic sclerosis (SSc)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].